Literature DB >> 9828992

Nithsdale schizophrenia surveys. 17. Fifteen year review.

C Kelly1, R G McCreadie, T MacEwan, S Carey.   

Abstract

BACKGROUND: In recent years there has been a shift to 'community care' and the introduction of several 'atypical' antipsychotic drugs. We report the impact of these changes.
METHOD: In Nithsdale, Dumfries and Galloway, Scotland, the population of patients with schizophrenia was identified in 1996. This census replicated a study carried out in 1981. The population with schizophrenia were compared on clinical and social variables. The whereabouts in 1996 of the 1981 population was determined.
RESULTS: In comparison with the 1981 population, more patients in 1996 had positive, negative and non-schizophrenic symptoms. More showed tardive dyskinesia. Social adjustment had not changed. They had spent less time in hospital; fewer (13%) were living with their parents; and fewer (8%) were employed. By 1996, 35% of the 1981 cohort had died (standardised mortality rate male-154; female-162).
CONCLUSIONS: The mental health of a community of people with schizophrenia living in a rural area in 1996 was poorer than in 1981.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828992     DOI: 10.1192/bjp.172.6.513

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  2 in total

1.  A study of an antipsychotic prescription pattern of patients with schizophrenia in a developing country.

Authors:  Smitha Ramadas; Praveenlal Kuttichira; T P Sumesh; Shijin A Ummer
Journal:  Indian J Psychol Med       Date:  2010-01

2.  Short-term functional outcome in psychotic patients: results of the Turku early psychosis study (TEPS).

Authors:  Raimo K R Salokangas; Tiina From; Tuula Ilonen; Sinikka Luutonen; Markus Heinimaa; Reetta-Liina Armio; Heikki Laurikainen; Maija Walta; Janina Paju; Anna Toivonen; Päivi Jalo; Lauri Tuominen; Jarmo Hietala
Journal:  BMC Psychiatry       Date:  2021-12-02       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.